Tivic Health amends Statera license; may pay royalties in securities, directs up to $5.6M to Avenue Capital

Valion Bio, Inc.

Amended license agreement gives Tivic discretion to pay future royalties in cash or its own securities.
Subsequent payments to Statera, up to $5.6M aggregate, will be paid directly to Avenue Capital on Statera's behalf.
Original exclusive license for Entolimod (TLR5 agonist) for Acute Radiation Syndrome and option for other indications unchanged.
License fee of $300K cash plus 945,785 common shares and convertible preferred shares already paid at closing in Feb 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.